Get the Stockscreener App
6.01
9.27%
0.51
Elicio Therapeutics Inc stock is traded at $6.01, with a volume of 75,388.
It is up +9.27% in the last 24 hours and down -26.53% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$5.50
Open:
$5.39
24h Volume:
75,388
Relative Volume:
1.58
Market Cap:
$95.88M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.2349
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
-22.85%
1M Performance:
-26.53%
6M Performance:
+30.65%
1Y Performance:
-20.08%
1-Day Range:
$5.15
$6.18
1-Week Range:
$4.7524
$7.48
52-Week Range:
$3.3419
$11.45
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
6.01 | 95.88M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know - MSN
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Elicio Therapeutics Advances Cancer Immunotherapy Pipeline - TipRanks
Elicio signals delay in mid-stage cancer vaccine study; shares slump - TradingView
Elicio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elicio Therapeutics, Inc. SEC 10-K Report - TradingView
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio's Latest Financial Results Reveal Key Clinical Milestones and 28.9-Month Survival Data - Stock Titan
(ELTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Elicio Therapeutics Names Preetam Shah CFO -March 24, 2025 at 08:17 am EDT - MarketScreener
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Elicio Therapeutics Appoints New Chief Strategy and Financial Officer - TipRanks
Elicio Therapeutics appoints new CSFO amid clinical trials - Investing.com
Strategic Move: Elicio Strengthens Leadership Team Ahead of Crucial Phase 2 Trial Results - Stock Titan
Elicio Therapeutics, Inc. (NASDAQ:ELTX) surges 13%; individual investors who own 49% shares profited along with insiders - simplywall.st
The hottest cancer vaccine companies you should know about - Labiotech.eu
With 36% ownership, Elicio Therapeutics, Inc. (NASDAQ:ELTX) insiders have a lot at stake - Yahoo Finance
Objective long/short (ELTX) Report - Stock Traders Daily
How to Take Advantage of moves in (ELTX) - Stock Traders Daily
Clal Biotech Completes Elicio Divestment and Initiates Loan Repayment - TipRanks
Knoll Capital Management, LLC Acquires Significant Stake in Elic - GuruFocus
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 - Insider Monkey
Elicio Therapeutics secures $10 million in direct offering - MSN
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data - Seeking Alpha
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Elicio Therapeutics Advances with New Clinical Updates - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
FDA Supports Registrational Strategy for ELI-002 in KRAS-Driven Cancers - Targeted Oncology
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - The Manila Times
Elicio Therapeutics Secures FDA Support for ELI-002 Cancer Therapy Phase 3 Strategy - StockTitan
(ELTX) Investment Report - Stock Traders Daily
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Benzinga
Serina Therapeutics Appoints Former Jazz Pharmaceuticals Finance Executive Karen Wilson to Board - StockTitan
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Trading (ELTX) With Integrated Risk Controls - Stock Traders Daily
Elicio Therapeutics Advances ELI-002 and Secures Funding - Yahoo Finance
Elicio reports promising cancer vaccine trial results By Investing.com - Investing.com Canada
Elicio Therapeutics Presents Updated Results from ELI-002 - GlobeNewswire
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO - The Bakersfield Californian
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 - Business Upturn
(ELTX) Investment Analysis and Advice - Stock Traders Daily
Elicio completes phase 2 enrollment for cancer vaccine By Investing.com - Investing.com Canada
Elicio completes phase 2 enrollment for cancer vaccine - Investing.com India
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment - GlobeNewswire
Elicio Therapeutics Completes Phase 2 Trial Enrollment for Pancreatic Cancer Treatment - StockTitan
SEC Form 424B3 filed by Elicio Therapeutics Inc. - Quantisnow
Elicio Therapeutics: Q3 Earnings Snapshot - mySA
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):